LMH STRATEGIC SOLUTIONS

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $30,000.00 income · posted Apr 18, 2025

Bills named in this filing 2

Lobbying activity 1

Medicare/Medicaid

Home Infusions Issues. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.